AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

International winds of uncertainty blow over NZ sharemarket
Markets Market Close

International winds of uncertainty blow over NZ sharemarket

Markets enter a quiet period after the reporting season. 

Infratil's renewables stake drops by US$133m
Markets

Infratil's renewables stake drops by US$133m

Infratil provided updated valuations on three investments.

John Anthony 07 Mar 2025
NZME board spill support builds towards 50%
Markets

NZME board spill support builds towards 50%

An update to the NZX says more shareholders are expressing support for board changes.

Pattrick Smellie 07 Mar 2025
Tech titans eye NZ's new golden visas
Policy

Tech titans eye NZ's new golden visas

Investors with tens of millions were 'priced out of the market'. Not any more.